Innovent Q2 Revenue Exceeds RMB 2 Billion; Hansoh Inks Deal for Lupeng's BTK Inhibitor LP-168
Innovent
High-end Biologics Developer
Hansoh Pharma
Pharmaceutical Research, Production, and Sales
Lupeng Pharmaceutical
Developer of New Anticancer Drugs
© Amino Observation - Innovative Drug Team Original Production
Author | Huang Kai
Innovent Bio Demonstrates Strength.
On August 8, Innovent Bio announced that in the second quarter of 2024, the company achieved total product revenue of over 2 billion RMB, representing a year-on-year growth of approximately 50%.
On the same day, Transtek Medical announced that the company achieved operating revenue of 499 million yuan in the first half of 2024, representing a year-on-year increase of 29.63%; net profit attributable to shareholders of the listed company was 34.85 million yuan, marking a year-on-year increase of 303.72%.
The internal circulation in the pharmaceutical industry is accelerating.
On August 8, Hansoh Pharma announced that it had reached a strategic cooperation with Lupeng Pharmaceutical to acquire the rights to the latter's BTK inhibitor LP-168 for all non-oncology indications in China.
According to the agreement, an upfront payment totaling no more than 729 million RMB is required, along with potential milestone payments for research and development, registration, and sales-based commercialization. Additionally, there will be tiered royalties based on future net product sales, with the royalty rate being a high double-digit percentage.
Lilly's Performance Exceeds Expectations.
On August 8, Eli Lilly released its second-quarter financial report. In the second quarter, the company's revenue was $11.3 billion, a year-on-year increase of 36%, with the market estimate at $9.98 billion. Eli Lilly expects full-year revenue to be between $45.4 billion and $46.6 billion, an increase of $3 billion from the previous estimate of $42.4 billion to $43.6 billion.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) Hansoh Pharma Introduces Lupeng Pharmaceutical's BTK Inhibitor
On August 8, Hansoh Pharma announced that it had reached a strategic cooperation with Lupeng Pharmaceutical to acquire the rights to all non-oncology indications of the latter's BTK inhibitor LP-168 in China. The deal involves an upfront payment and potential milestone payments for R&D, registration, and commercialization based on sales, totaling no more than 729 million RMB, as well as tiered royalties of up to double-digit percentages based on future net product sales.
/ 02 /
Capital Information
1) Transtek Medical's Net Profit Increased by 303.72% Year-on-Year in the First Half of the Year
On August 8, Transtek Medical announced that the company achieved operating revenue of 499 million yuan in the first half of 2024, representing a year-on-year increase of 29.63%; net profit attributable to shareholders of the listed company was 34.85 million yuan, representing a year-on-year increase of 303.72%.
2) Innovent Bio's Q2 Revenue Exceeds 2 Billion Yuan
On August 8, Innovent Bio announced that in the second quarter of 2024, the company achieved total product revenue of over 2 billion RMB, representing a year-on-year growth of approximately 50%.
/ 03 /
Pharmaceutical News
1) Hengbang Pharma's Injectable HS-20093 Receives Clinical Approval
On August 8, according to the CDE website, Hansoh Pharma's HS-20093 for injection received clinical approval. It is proposed to be used in combination with bevacizumab (with or without chemotherapy) or cetuximab (with chemotherapy) for the treatment of patients with metastatic advanced colorectal cancer.
2) StarLink Peptide's Injectable SC-102 Receives Clinical Approval
On August 8, according to the CDE official website, Xinglian Peptide Biotech's injectable SC-102 received clinical approval for the treatment of advanced malignant solid tumors expressing EphA2.
3) Huihe Bio's CC312 Lyophilized Powder Injection Receives Clinical Approval
On August 8, according to the CDE website, Huihe Bio's CC312 Lyophilized Powder Injection received clinical approval and is intended for use in systemic lupus erythematosus.
4) Roche's Xofluza for Children Officially Launched in China
On August 8, Roche China announced the official launch of its anti-influenza drug, Baloxavir Marboxil for Oral Suspension, in China. It is indicated for the treatment of children aged 5 to less than 12 years with uncomplicated influenza A or B, including previously healthy patients as well as those at high risk of influenza-related complications.
5) Changyu Pharmaceutical's Innovative Painkiller XG005 Successfully Completes Phase IIb Clinical Trial for Knee Osteoarthritis Pain
On August 8, Changyu Pharmaceuticals announced that the Phase IIb clinical study evaluating the efficacy and safety of the innovative analgesic XG005 oral tablets (XG005) for treating pain in patients with knee osteoarthritis achieved significant positive results.
/ 04 /
Instrument Tracking
1) Minimally Invasive Melody Dual-Lumen Microcatheter Approved for Marketing
On August 8, according to the NMPA website, MicroPort Melody Dual-Lumen Microcatheter was approved for marketing.
2) Multiple devices, including Weqiang Medical's Thoracic Aortic Stent System, have been approved for marketing.
On August 8, according to the NMPA website, multiple devices from Weiqiang Medical, including the thoracic aortic stent system and peripheral balloon dilation catheter, were approved for marketing.
3) Multiple devices, including Coviden's intracranial thrombectomy stent, approved for marketing
On August 8, according to the NMPA website, multiple devices from Coviden Medical, including intracranial thrombectomy stents and mechanically detachable coils, were approved for marketing.
4) NorthX BioTech's Single-Use Microcatheter Approved for Marketing
On August 8, according to the NMPA website, Beixins Life's disposable microcatheter was approved for marketing.
/ 05 /
Digital Healthcare Daily
1) Internet Consultations Must Be Corrected at the Source
On August 8, the China Women's Daily published an article stating that addressing the chaos in internet-based medical treatment is not just a matter of regulatory norms. Only by deeply integrating with offline medical services can we achieve extended integration and restore the original purpose of online consultations. Therefore, to achieve high-quality development in internet healthcare, it is essential to first promote the availability of quality medical resources online, especially by encouraging more public hospitals to provide internet-based medical services, allowing more credible services to dominate the main platform for online consultations. Secondly, efforts should focus on refining roles, playing to strengths, and avoiding weaknesses, guiding physical medical institutions to extend their services online, ensuring effective matching between supply and demand, and truly avoiding the awkward situation of "randomly seeking medical advice" online.
2) JD Health Hosts Global Medical AI Innovation Competition
Recently, the preliminary round of JD Health·Global Medical AI Innovation Competition has successfully concluded. This competition, initiated by JD Health, aims to explore cutting-edge technologies and innovative applications in the medical industry, and to collaborate with industry, academia, and research forces to promote high-quality development in the medical services sector.
3) JD Daojia Quick Inspection Launches New Allergen, HPV and Other Testing Services
Recently, JD Health Internet Hospital launched the "Online Lab Test Order Service," integrating professional medical testing into the online consultation process. Currently, more than 70 blood test items are available, including tests for allergens, HPV, and others.
/ 04 /
Overseas Pharmaceutical News
1) Eli Lilly's Performance Exceeds Expectations
On August 8, Eli Lilly released its second-quarter financial report. In the second quarter, the company's revenue was $11.3 billion, a year-on-year increase of 36%, with the market estimate at $9.98 billion. Eli Lilly expects full-year revenue to be between $45.4 billion and $46.6 billion, an increase of $3 billion from the previous estimate of $42.4 billion to $43.6 billion.
2) Extended-Release Parkinson's Disease Drug Approved by FDA
On August 7, Amneal Pharmaceuticals announced that the U.S. FDA had approved Crexont extended-release capsules for the treatment of Parkinson's disease (PD).
PS: Welcome to scan the QR code below and add the WeChat ID of Amino Jun for communication.
